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Interventional Cardiology
New Stent Design Does Not Inhibit Local Coronary Vasodilation
The Nobori (Teroumo Corp., Tokyo, Japan) coronary stent system employs abioresorbable polymer from which biolimus A9 is eluted. Biolimus A9 is a
sirolimus derivative that ismore lipophillic, which should promote increased uptake in
local endothelium. Hamilos and colleagues measured endothelium-dependent and
-independent coronary vasomotion proximally and distally to the stent 9months after
randomization to either a biolumus-eluting stent (BES) or sirolimus-eluting stent
(SES). Those with a biolumis stent were more likely to vasodilate during rapid pacing
than those with a sirolimus stent, particulary in the segment distal to the stent, while
endothelium-independent vasomotionwas not different. These results suggest that the
Nobori stent does not inhibit endothelium-dependent vasomotion to the extent that
sirolimus-eluting stents do. See page 2123. See figure.
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Vascular Function
Flavanols Improve Endothelial Function
Epidemiological data has shown that diets rich in flavanols are associated withreduced cardiovascular risk. Balzer and colleagues studied the effects of flavanols
on endothelial function using a placebo-controlled study with flow-mediated dilation
(FMD) of the brachial artery. After a preliminary exploratory study, subjects were
randomized to drink a cocoa-based mix containing flavanols or placebo for 30 days;
FMD improved by 30% in those assigned to flavanols. Treatment was well-tolerated
and there were no changes in the response to nitroglycerin, blood pressure, heart rate,
or glycemic control. These findings suggest that a diet rich in flavanols, or supple-
mented with flavanols, can improve endothelial function in diabetics. See page
2141. See figure.
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Heart Rhythm Disorders
AF Begets AF
Patients with a history of atrial fibrillation (AF) have shorter effective refractoryperiods (ERPs) andmore pronounced decremental conduction properties in their
pulmonary veins (PVs). However, it is not known if these differences identify patients
at risk for AF or are caused by previous episodes of AF. Rostock and colleagues studied
patientswithnohistory ofAF.TheERPs and conduction timeswere determined, both
before and after a 15-min episode of intentionally induced AF. At baseline, the PVs
displayed significantly longer ERPs than the atria. After a short episode of AF, the ERP
of the PVswasmarkedly reduced and their conduction velocity was slowed, whichwas
associated with an increased susceptibility to induction of AF. These findings suggest
that AF does beget AF, by altering the conduction properties of the PVs. See page
2153. See figure.
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Heart Failure
New Alogrithm Predicts the Risk of RV Failure After LVAD Implantation
Right ventricular (RV) failure following left ventricular assist device (LVAD)surgery is associated with increased mortality, but identifying LVAD candidates
at risk for RV failure remains difficult. Matthews and colleagues retrospectively re-
viewed a database of nearly 200 LVAD implants for pre-operative predictors of RV
failure. An RV failure risk score (RVFRS) was then developed which included 4
components: vasopressor requirement, aspartate aminotransferase80 IU/l, bilirubin
2.0 mg/dl, and creatinine2.3 mg/dl. The odds of RV failure for patients with an
RVFRS5.5 were 15-fold greater than those with an RVFRS3.0, and these scores
also predicted 6-month mortality. The RVFRS stratifies the risk of RV failure and
death following LVAD implantation. See page 2163. See figure.
Biomarkers
SCUBE1 May Be A Serum Biomarker for Platelet Activation
After stimulation by thrombin, SCUBE1 (signal peptide-CUB-EGF domain con-taining protein 1) is released from platelets as smaller soluble fragments which are
then incorporated into thrombus.Dai and colleaguesmeasured plasma concentrations
of SCUBE1 from 40 subjects with acute coronary syndrome (ACS) and 40 with acute
ischemic stroke (AIS) and compared these levels to those of healthy controls or patients
with stable coronary artery disease (CAD). Plasma SCUBE1 concentration was virtu-
ally undetectable in healthy controls andCADpatients, but was significantly higher in
ACS and AIS patients. The increase in plasma SCUBE1 concentration was an inde-
pendent predictor of stroke severity. Plasma SCUBE1 concentration may serve as
useful biomarker of platelet activation in acute thrombotic events. See page 2173.
